In summary, our results showed a novel therapeutic strategy by co-targeting BET bromodomain BRD4 and RAC1 signaling pathways in different molecular subtypes of breast cancer including luminal-A, TNBC and HER-2 positive breast cancer. This evidence concerns the gene RAC1 and breast carcinoma.